Share on StockTwits

Research analysts at Roth Capital lifted their target price on shares of Durata Therapeutics (NASDAQ:DRTX) from $21.00 to $24.00 in a report released on Tuesday. The firm currently has a “buy” rating on the stock. Roth Capital’s target price indicates a potential upside of 42.10% from the company’s current price.

Shares of Durata Therapeutics (NASDAQ:DRTX) traded down 10.56% during mid-day trading on Tuesday, hitting $15.106. 1,443,754 shares of the company’s stock traded hands. Durata Therapeutics has a one year low of $6.70 and a one year high of $17.20. The stock’s 50-day moving average is $14.08 and its 200-day moving average is $12.86. The company’s market cap is $402.4 million.

Durata Therapeutics (NASDAQ:DRTX) last announced its earnings results on Thursday, May 8th. The company reported ($0.62) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.64) by $0.02. On average, analysts predict that Durata Therapeutics will post $-2.34 earnings per share for the current fiscal year.

DRTX has been the subject of a number of other recent research reports. Analysts at RBC Capital raised their price target on shares of Durata Therapeutics from $19.00 to $23.00 in a research note on Tuesday. They now have an “outperform” rating on the stock. Separately, analysts at Jefferies Group raised their price target on shares of Durata Therapeutics from $14.00 to $15.00 in a research note on Tuesday. They now have a “hold” rating on the stock. Finally, analysts at MLV & Co
initiated coverage on shares of Durata Therapeutics in a research note on Friday. They set a “buy” rating and a $21.00 price target on the stock. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Durata Therapeutics has a consensus rating of “Buy” and an average price target of $19.38.

Durata Therapeutics, Inc is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.